BUZZ-Zai Lab up after lung cancer drug meets main goal in late-stage trial

Reuters04-01

** U.S.-listed shares of China-based drug maker Zai Lab Ltd

jump 3.3% to $16.55 premarket

** ZLab's partner Bristol Myers Squibb said late on Thursday that its drug KRAZATI had met the main goal in a late-stage study for non-small cell lung cancer (NSCLC) with a mutation

** Drug also met a key secondary goal of the study

** ZLAB expects to submit a New Drug Application for KRAZATI to China's National Medical Products Association for this indication as second or a later-line treatment this year

** BMY will complete a full evaluation of available data & discuss the results with health authorities

** Up to Thursday's close, ZLAB's U.S. shares down 41.4% YTD

(Reporting by Atharva Singh in Bengaluru)

((Atharva.singh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment